| Literature DB >> 30430751 |
Christiane Klec1,2, Felix Prinz1,2, Martin Pichler1,2,3.
Abstract
Altered expression levels of the long noncoding RNA (lncRNA) nuclear-enriched abundant transcript 1 (NEAT1) have been reported in different types of cancer. More than half of the NEAT1 studies in cancer have been published within the last 2 years. In this review, we discuss very recent developments and insights into NEAT1 contribution to carcinogenesis. Summarizing the literature, it becomes obvious that NEAT1 is a lncRNA highly de-/upregulated in a variety of cancer entities, in which it primarily acts as a competing endogenous RNA (ceRNA) which sponges tumor-suppressive microRNA (miRNA). The sponged miRNA lose their ability to degrade, silence, or hamper translation of their downstream-mostly oncogenic-target transcripts, ultimately promoting carcinogenesis. This role of NEAT1 function in tumorigenesis suggests it may be a prognostic biomarker as well as potential therapeutic target, pending the completion of further studies into the underlying mechanisms.Entities:
Keywords: NEAT1; cancer; ceRNA; lncRNA; miRNA
Mesh:
Substances:
Year: 2018 PMID: 30430751 PMCID: PMC6322192 DOI: 10.1002/1878-0261.12404
Source DB: PubMed Journal: Mol Oncol ISSN: 1574-7891 Impact factor: 6.603
Figure 1Schematic representation of the consequences of elevated NEAT1 expression levels in the context of cancer. (Upper panel) In normal tissue, NEAT1 expression levels are low; therefore, tumor‐suppressive miRNA are not sponged which enables them binding to oncogenic miRNA resulting in a hampered translation and low levels of oncogenic proteins. (Lower panel) In cancer tissue and cancer cell lines NEAT1 expression levels are high. Tumor‐suppressive miRNA are sponged by NEAT1 resulting in reduced binding of these miRNA to oncogenic mRNA. High numbers of these mRNA are translated to oncogenic proteins and cancer cell proliferation, invasion, migration, etc. are promoted.
Interplay of certain miRNA with NEAT1 in diverse cancer types and the corresponding modulated protein targets (arrows indicate upregulation (↑) or downregulation (↓) of the respective factor). Ca, carcinoma; PBS, predicted binding site; Luc, Luciferase promotor assay; PD, RNA pull‐down assay; bis‐sequ., bisulfite sequencing
| Cancer type | miRNA | 3′–5′ sequence | PBS to NEAT1 | PBS investigated in literature | Experimental method | Target protein | References |
|---|---|---|---|---|---|---|---|
| Nonsmall lung cancer | 181a‐5p |
| 4 | 1066 | Luc, PD | ↑HMBG2 | Li |
| 377‐3p |
| 5 | No details | Luc | ↑E2F3 | Zhang | |
| 98‐5p |
| 3 | 4179 | Luc, PD | ↑MAPK6 | Wu | |
| Breast cancer | 101‐3p |
| 1 | 12 605 | Luc | ↑EZH2 | Qian |
| 211‐5p |
| 3 | 3209 | Luc | ↑HMGA2 | Li | |
| 488 |
| 2 | 2331 | Luc | ↑ZEB1 | Jiang | |
| 548ar‐3p |
| 0 | 2443 RNA hybrid | qPCR | Ke | ||
| 129‐5p |
| 3 | No details | qPCR, bis‐sequ. | ↑WNT4 | Lo | |
| Hepatocellular Ca | 129‐5p |
| 3 | 10 197 | PD | ↑VCP, ↓κB | Fu |
| 613 |
| 5 | 1863 | Luc | ↑DCLK1 | Wang | |
| 485‐5p |
| 5 | 4456 | Luc | ↑STAT3 | Zhang | |
| 139‐5p |
| 2 | 1588 | Luc, PD | ↑TGFβ1 | Tu | |
| 124‐3p |
| 3 | 2928 | Luc | ↑ATGL | Liu | |
| Ovarian Cancer | 34a‐5p |
| 5 | 14 939 | Luc | ↑BCL2 | Ding |
| 194‐5p |
| 2 | 3639 | Luc | ↑ZEB1 | An | |
| 382‐3p |
| 3 | 22 189 | Luc | ↑ROCK | Liu | |
| Gastric Cancer | 506‐3p |
| 3 | 2928 | Luc, PD | ↑STAT3 | Tan |
| Cervical Ca | 193b‐3p |
| 3 | 1991 | Luc, PD | ↑Cyclin D1 | Han |
| 101 |
| 1 | 12 605 | Luc | ↑FOS | Wang and Zhu ( | |
| Nasopharyngeal Ca | let‐7a‐5p |
| 3 | 14 917 | Luc | ↑Ras‐MAPK | Liu |
| 124‐3p |
| 3 | 3252 | Luc, PD | ↑NFκB | Cheng and Guo ( | |
| Oral squamous cell Ca | 129‐5p |
| 3 | ‐ | Luc | ↑CTBP2 | Li |
| 365‐3p |
| 3 | 1901 | Luc | ↑RGS20 | Huang | |
| Clear cell renal Ca | 34a‐5p |
| 5 | 14 939 | Luc | ↑c‐MET | Liu |
| Osteosarcoma | 34c‐5p |
| 5 | 14 938 | qPCR | ↑BCL2+ ↑CCND1 | Hu |
| 194‐5p |
| 2 | 3639 | Luc | Wang | ||
| Glioblastoma | 107 |
| 1 | 1514 | Prediction, functional assays | ↑CDK6 | Yang |
| let‐7e‐5p |
| 3 | 14 917,14 737 | Luc | ↑NRAS | Gong |
Investigated miRNA binding site was not predicted with Starbase database.